Lazard Asset Management LLC Glycomimetics Inc Transaction History

Lazard Asset Management LLC

  • $61.8 Billion
  • Q4 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 13, 2019
SELL
$8.47 - $14.71 $409,600 - $711,360
-48,359 Closed
0 $0
Q3 2018

Nov 13, 2018
BUY
$13.7 - $17.12 $662,518 - $827,906
48,359 New
48,359 $696,000
Q2 2018

Aug 13, 2018
SELL
$14.63 - $19.19 $236,859 - $310,686
-16,190 Closed
0 $0
Q1 2018

May 14, 2018
BUY
$16.06 - $25.35 $260,011 - $410,416
16,190 New
16,190 $262,000

Others Institutions Holding GLYC

# of Institutions
43
Shares Held
30.3M
Call Options Held
51K
Put Options Held
1.4K
View Full List

About GLYCOMIMETICS INC

GLYC Quotes by TradingView
  • Ticker GLYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,423,900
  • Market Cap $14.7M
  • Description
  • GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...
More about GLYC
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email